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Background: Fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD), a rapidly emerging and
widely recognized liver disease today, is regarded as a hepatic manifestation of metabolic syndrome. Helicobacter pylori,
one of the most common pathogens worldwide, has been reported to be associated with metabolic syndrome, but
whether there is a direct association with FLD is as of yet unclear. The aim of this study was to clarify the association of
FLD and NAFLD with causative background factors including Helicobacter pylori infection.
Methods: This was a cross-sectional study of Japanese adults who received medical checkups at a single medical center
in 2010.Univariate and multivariate statistical analysis was performed to evaluate background factors for ultrasonography
diagnosed FLD. Subjects free from alcohol influence were similarly analyzed for NAFLD.
Results: Of a total of 13,737 subjects, FLD was detected in 1,456 of 6,318 females (23.0 %) and 3,498 of 7,419 males (47.1%).
Multivariable analyses revealed that body mass index (standardized coefficients of females and males (β-F/M) =143.5/102.5),
serum ALT (β-F/M = 25.8/75.7), age (β-F/M = 34.3/17.2), and platelet count (β-F/M= 17.8/15.2) were positively associated
with FLD in both genders. Of the 5,289 subjects free from alcohol influence, NAFLD was detected in 881 of 3,473 females
(25.4%) and 921 of 1,816 males (50.7%). Body mass index (β-F/M= 113.3/55.3), serum ALT (β-F/M = 21.6/53.8), and platelet
count (β-F/M = 13.8/11.8) were positively associated with NAFLD in both genders. Metabolic syndrome was positively
associated with FLD and NAFLD only in males. In contrast, Helicobacter pylori infection status was neither associated with
FLD nor NAFLD regardless of gender.
Conclusions: Body mass index, serum ALT and platelet count were significantly associated with FLD and NAFLD, whereas
infection of Helicobacter pylori was not.
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Fatty liver disease (FLD) is the most common chronic
liver disease in the world today. It is caused by multiple
factors such as nutritional disorders, dyslipidemia, insu-
lin resistance, genetic factors, etc. [1]. Especially, alcohol
intake and metabolic abnormalities such as insulin re-
sistance have been reported to be the main causes for
FLD [2,3]. However, recent epidemiological studies have
not been enough to elucidate complicated risk factors
for FLD, despite the high prevalence and importance of
the disease [4-6]. FLD is generally divided into alcoholic
fatty liver disease (AFLD) and non-alcoholic fatty liver
disease (NAFLD) according to amounts of alcohol in-
take. The boundary value of alcohol intake between
AFLD and NAFLD is tentatively defined [7], but the ef-
fect of moderate alcohol intake upon FLD still leaves
much room for discussion [8-10].
NAFLD is also common all over the world including
Eastern countries [11], but the reported prevalence rate of
NAFLD varies widely [12-17]. NAFLD is a concerning dis-
ease not only because of its high prevalence but also its
potential risk of fatal diseases such as liver failure, hepato-
cellular carcinoma (HCC), cardiovascular disease, and so
on [18,19]. NAFLD is regarded as a hepatic manifestation
of metabolic syndrome (MS) [20]. Machado M et al. re-
ported that the prevalence of NAFLD was 91% in obese
patients who had undergone bariatric surgery [21]. It has
also been reported that type 2 diabetes and other features
of MS are strongly related to NAFLD [22,23].
The relationship between NAFLD and microbes in the
gut has been occasionally reported [24,25]. As ”Gut-Liver
Axis” has been widely noticed [26,27], several liver dis-
eases including NAFLD are thought to be influenced by
gastro-intestinal tract environments mainly decided by
existing microbes. Among enormously varied microbes, to
our knowledge today, Helicobacter pylori (H. pylori) shows
the greatest effect on the upper gastro-intestinal environ-
ment. It is well known that approximately 50% of the glo-
bal population is estimated to be infected by H. pylori
[28], and is also well established that chronic infection of
H. pylori can be a cause of chronic atrophic gastritis, pep-
tic ulcer disease and gastric cancer [29,30]. Recently, not a
few reports concerning the influence of H. pylori on
various extra-alimentary organs have been accumulated
[31-34]. Among these putative extra-alimentary disorders
caused by H. pylori, the relation to MS is still controversial
[35-42]. Though there have been many reports discussing
the relationship between H. pylori and MS, issues to clarify
still remain.
Based on these reports, we hypothesized that H. pylori
has some associations with FLD including NAFLD.
There has previously been only one similar small-scale
study which concluded that H. pylori infection is associ-
ated with NAFLD [43]. The aim of this study was toclarify the background factors of FLD and NAFLD, and
the influence of H. pylori infection on these diseases.
Methods
Study subjects
This was a cross-sectional study of Japanese asymptom-
atic adults who received medical checkups at Kameda
Medical Center Makuhari (Chiba-shi, Chiba, Japan) in
2010, and voluntarily consented to entry into our study.
This study was approved by the ethics committees of
The University of Tokyo, and written forms of informed
consent were obtained from all study participants ac-
cording to the Declaration of Helsinki.
If the subject had health checkups twice in 2010, the
former data was used. Criteria for exclusion were age
less than 20 years, insufficient data, or poor answers to
the questionnaire.
Questionnaires
A detailed questionnaire including inquiries about upper
gastrointestinal tract-related symptoms [44-46], medical
history, family history, lifestyle factors, etc. was filled out
by all the participants. This questionnaire has already
been used and validated in several previous reports
[31,46-49]. Answers filled out by the participants were
carefully checked by the nursing staff before being recorded
into our study database. The questionnaire included five
yes-no questions regarding regular intake of anti-
cholesterol drugs, anti-hypertensive drugs, anti-diabetic
drugs and corticosteroids, and history of gastrectomy. We
additionally graded alcohol intake frequency on a 5-grade
scale (never, rarely, sometimes, almost daily, and daily per
week). In this analysis, “never” and “rarely” are regarded as
non-drinker, “sometimes” is regarded as occasional-drinker,
and “almost daily” and “daily” are regarded as daily-drinker.
As for the amount of alcohol intake, we defined one drink
unit is equivalent to a 12-ounce beer, a 4-ounce glass of
wine, or a 1-ounce shot of hard liquor. And we also catego-
rized the subjects into four groups according to: less than
two units at a time, two to three units at a time, three to
four units at a time and more than four units at a time. We
further categorized smoking habit into three groups,
current smoking (current-smoker), past habitual smoking
(former-smoker), and lifelong nonsmoking (never-smoker).
Diagnosis of fatty liver disease (FLD)
Fatty liver disease (FLD) was diagnosed by abdominal
ultrasonography. Routine ultrasonography evaluation of
six intra-abdominal organs (liver, gallbladder, pancreas,
kidneys, spleen, and abdominal aorta) was performed by
well-trained operators. Characteristic findings of fatty
liver are as follows; i) an increase of liver brightness, ii)
an increase of hepato-renal echo contrast, iii) deep at-
tenuation of hepatic echo, iv) existence of intra-hepatic
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and vi) existence of borderline blurring between liver
and gallbladder, or right kidney. Fatty liver was diag-
nosed when the ultrasonographic findings satisfied both
i) and ii) in addition to at least one of the findings be-
tween iii) to vi) [50]. The diagnosis was double-checked
by the operators and gastroenterologists.
Definition of non-alcoholic fatty liver disease (NAFLD)
NAFLD was defined according to the guideline published
from AASLD (American Association for the Study of Liver
Diseases), ACG (American College of Gastroenterology),
and AGA (American Gastroenterological Association) in
2012 [7]. In this present study, we defined NAFLD accord-
ing to the characteristic findings as follows; i) with evi-
dence of fatty liver by ultrasonography (see above), and ii)
with no causes for secondary hepatic fat accumulation in-
cluding any viral hepatitis and steatogenic medication.
With regard to alcohol intake, more than 21 drink units
per week in males and more than 14 drink units per week
in females were widely recognized as significant alcohol in-
take. To exclude alcohol influence strictly, we omitted all
occasional-drinkers, all daily-drinkers, and Non-drinkers
who occasionally drunk more than four units at one time.
Evaluation of serum anti-helicobacter pylori antibody
Serum anti-H. pylori antibody was measured using a
commercial EIA kit (E-plate “EIKEN” H. pylori antibody,
EIKEN Chemical Co Ltd, Tokyo, Japan) as we have pre-
viously reported [48]. According to the manufacturer’s
instruction, an antibody titer above 10 U/ml was consid-
ered as H. pylori-positive. We omitted individuals who
had histories of eradications of H. pylori from analysis.
Definition of metabolic syndrome (MS)
The definition of MS was based on the Japanese criteria
published in 2005 [51]. The diagnostic criteria is visceral
obesity in combination with any two of the following
three standards; i) systolic blood pressure (SBP) greater
than 130 mmHg and/or diastolic blood pressure (DBP)
greater than 85 mmHg, ii) triglyceride (TG) greater than
150 mg/dL and/or high-density lipoprotein (HDL) chol-
esterol less than 40 mg/dL, iii) fasting blood sugar (FBS)
greater than 110 mg/dL. Visceral obesity was defined as
a waist girth of at least 85 cm in male and at least 90 cm
in female.
Statistical analyses
We analyzed data of female and male separately. We
used JMP11 software (SAS Institute Japan) for statistical
analyses. In univariate analyses, odds ratios and 95%
confidence intervals were calculated and a p value of
<0.01 was considered to indicate statistical significance.
Following continuous variables were compared using theWelch’s t test or Wilcoxon’s rank-sum test and following
categorical variables were compared using the Fisher’s
exact test as appropriate for fatty liver status: age (con-
tinuous data), height (continuous data), weight (continu-
ous data), BMI (body mass index, continuous data), AST
(serum aspartate aminotransferase, continuous data),
ALT (serum alanine aminotransferase, continuous data),
GGT (gamma-glutamyl transpeptidase, continuous data),
T-Bil (total bilirubin, continuous data), ALB (serum al-
bumin, continuous data), PLT (platelet, continuous
data), TC (total cholesterol, continuous data), HDL-C
(high-density lipoprotein cholesterol, continuous data),
LDL-C (low-density lipoprotein cholesterol, continuous
data), TG (triglyceride, continuous data), HbA1c (con-
tinuous data), FBS (fasting blood sugar, continuous data),
SBP (systolic blood pressure, continuous data), DBP
(diastolic blood pressure, continuous data), Waist girth
(continuous data), presence of MS (metabolic syndrome,
categorical data), habit of drinking (categorical data),
habit of smoking (categorical data), and H. pylori infec-
tion status (anti-H. pylori antibody, categorical data).
Among the continuous variables, AST, ALT, GGT and
TG were compared by Wilcoxon’s rank-sum test and the
other continuous variables were compared by Welch’s t
test.
In multivariate analysis, standardized coefficient and
standard error of each variable for FLD and NAFLD
were calculated by the regularized logistic regression via
the elastic net to avoid the correlations between each




Of the 20,773 subjects who participated in this study, we
excluded 2,119 subjects due to age less than 20 years old
(2), insufficient data of several examination including
ultrasonography and anti-H. pylori antibody (1,814), or
poor answers to the questionnaire (1,141). The 2,119 ex-
cluded subjects had the same background characteristics
as the included 18,654 subjects (Additional file 1: Table
S1). Of the 18,654 subjects who met inclusion criteria
(Figure 1), we further excluded 3,809 subjects who were
positive for HBsAg and/or HCVAb (261), who had a
history of gastrectomy (174), and who took anti-
hypertensive drugs (2,256), anti-diabetic drugs (481),
anti-cholesterol drugs (1,515), or corticosteroids (186),
since these factors might affect fatty liver status and/or
some essential laboratory tests [52,53]. Finally, we further
excluded 1,108 subjects who had a history of H. pylori
eradication.
The primary study population of 13,737 subjects was
comprised of 6,318 females and 7,419 males. Among
them, fatty liver (FLD) was detected in 1,456 of 6,318
13,737 subjects analyzed
(6,318 females and 7,419 males)
2,119 excluded due to age less than 20 years old (2),
insufficient data of several examination (1,814), or poor 
answers to the questionnaire (1,141)
18,654 met inclusion criteria
3,374 subjects taking antihypertensive drugs (2,256), 
antidiabetic drugs (481), anti-cholesterol drugs (1,515), 
or corticosteroids (186) were excluded.
20,773 individuals attended
261 excluded due to positive for HBs antigen or HCV 
antibody
174 excluded due to history of gastrectomy
3,473 females and 1,816 males
are not affected by alcohol
2,845 females and 5,603 males
are affected by alcohol
1,108 excluded due to history of H.pylori eradication
Figure 1 Of the 20,773 asymptomatic adults attended, 13,737 subjects were mainly analyzed in our present study. The subcategory of
5,289 subjects who were not affected by alcohol was also analyzed. Each figure presenting excluded patients was overlapping at the same box.
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also analyzed specific subjects who drank very little or
no alcohol to remove the effects of alcohol intake to
fatty liver status: after excluding all occasional-drinkers,
all daily-drinkers, and non-drinkers who drank more
than four units at a time, the residual 5,289 subjects
(3,473 females and 1,816 males) were analyzed. Among
them, fatty liver (i.e., NAFLD) was detected in 881 of
3,473 females (25.4%) and 921 of 1,816 males (50.7%).Associated factors for fatty liver disease (FLD) based on
the univariate analysis
We analyzed 19 continuous variables and 4 categorized
variables and their association with fatty liver disease
(Table 1, Table 2). Among the 23 examined factors, age,
weight, BMI, AST, ALT, GGT, T-Bil, PLT, TC, HDL-C,
LDL-C, TG, HbA1c, FBS, SBP, DBP, waist girth, presence
of MS and drinking habit were statistically significant back-
ground factors in both genders. Height, ALB, smoking
habit and H. pylori infection status were statistically signifi-
cant background factors in one gender.According to the results of univariate analyses and
multicollinearity (0.8957 in females and 0.8723 in males
between weight and BMI, 0.8521 in females and 0.7791
in males between AST and ALT), we excluded height,
weight, AST and smoking habit from the next multivari-
ate analysis. We adopted MS as a representative of waist
girth, TC, HDL-C, LDL-C, TG, FBS, HbA1c, SBP and
DBP. Consequently, we focused on the following nine
variables for multivariate analysis: age, BMI, ALT, GGT,
T-Bil, PLT, MS, drinking habit, and H. pylori infection
status.Associated factors for fatty liver disease (FLD) based on
the multivariate analysis
As shown in Table 3, the generalized regression analysis
demonstrated that BMI, ALT, age, and PLT were posi-
tively associated with FLD in both genders, and MS was
positively associated only in males. Daily-drinking habit
was negatively associated with FLD only in male. In con-
trast, GTT, T-Bil, and H. pylori infection status were not
associated with the presence of FLD.
Table 1 Characteristics of the 13,737 subjects (6,318 females and 7,419 males) focusing on the presence of fatty liver











Age (years old) 50.3 ± 7.9 46.9 ± 8.6 <0.0001* 48.7 ± 8.4 48.1 ± 9.5 0.0012*
Height (cm) 157.3 ± 5.6 158.2 ± 5.4 <0.0001* 170.8 ± 5.8 171.0 ± 5.9 0.0717
Weight (kg) 61.8 ± 9.6 51.4 ± 6.2 <0.0001* 72.8 ± 9.7 64.6 ± 7.8 <0.0001*
BMI (kg/m2) 25.0 ± 3.6 20.5 ± 2.2 <0.0001* 24.9 ± 2.8 22.1 ± 2.2 <0.0001*
AST (IU/l) 21.2 ± 8.9 19.0 ± 5.4 <0.0001* 24.6 ± 10.0 21.3 ± 17.1 <0.0001*
ALT (IU/l) 23.0 ± 16.7 16.0 ± 7.6 <0.0001* 33.5 ± 22.6 21.6 ± 15.9 <0.0001*
GGT (IU/l) 28.3 ± 27.8 19.3 ± 17.3 <0.0001* 55.6 ± 58.2 38.8 ± 38.3 <0.0001*
T-Bil (mg/dl) 0.71 ± 0.27 0.76 ± 0.27 <0.0001* 0.87 ± 0.35 0.90 ± 0.37 0.0045*
ALB (g/dl) 4.26 ± 0.21 4.25 ± 0.21 0.1028 4.40 ± 0.22 4.36 ± 0.22 <0.0001*
PLT (104/μl) 26.1 ± 5.9 23.7 ± 5.4 <0.0001* 23.9 ± 4.9 22.9 ± 4.7 <0.0001*
TC (mg/dl) 214.0 ± 34.1 198.8 ± 33.0 <0.0001* 207.7 ± 32.5 195.4 ± 30.5 <0.0001*
HDL-C (mg/dl) 64.7 ± 14.2 75.8 ± 15.4 <0.0001* 54.1 ± 12.7 63.8 ± 15.2 <0.0001*
LDL-C (mg/dl) 135.0 ± 32.3 114.2 ± 29.9 <0.0001* 134.8 ± 30.2 119.4 ± 28.9 <0.0001*
TG (mg/dl) 107.2 ± 80.8 68.2 ± 32.0 <0.0001* 151.3 ± 97.6 98.7 ± 62.6 <0.0001*
HbA1c (%) 5.52 ± 0.56 5.30 ± 0.33 <0.0001* 5.50 ± 0.62 5.29 ± 0.37 <0.0001*
FBS (mg/dl) 94.9 ± 15.2 88.3 ± 8.5 <0.0001* 100.1 ± 16.4 94.1 ± 10.0 <0.0001*
SBP (mmHg) 118.8 ± 16.5 107.7 ± 14.5 <0.0001* 121.4 ± 15.0 115.4 ± 14.7 <0.0001*
DBP (mmHg) 73.9 ± 10.5 67.2 ± 9.6 <0.0001* 77.0 ± 10.1 73.0 ± 9.8 <0.0001*
Waist (cm) 87.2 ± 8.6 75.7 ± 6.5 <0.0001* 87.4 ± 7.1 79.8 ± 6.4 <0.0001*
FLD: fatty liver disease. Data show mean ± SD (standard deviation) of each variable. By applying the Welch’s t test or Wilcoxon analysis, p values were calculated.
The level of significance was set below 0.01 (*).
Table 2 Characteristics of the 13,737 subjects (6,318 females and 7,419 males) focusing on the presence of fatty liver












Non-MS 1391 (22.3 %) 4860 (77.6 %) 2945 (43.5 %) 3832 (56.5 %)
MS 65 (97.0 %) 2 (3.0 %) 553 (86.1 %) 89 (13.9 %)
Alcohol <0.0001* <0.0001*
Non-drinker 884 (25.3 %) 2604 (74.7 %) 951 (50.8 %) 923 (49.3 %)
Occasional-
drinking
368 (20.2 %) 1456 (79.8 %) 1114 (49.9 %) 1120 (50.1 %)
Daily-drinker 204 (20.3 %) 802 (79.7 %) 1433 (43.3 %) 1878 (56.7 %)
Smoking 0.0467 0.0045*
Current-smoker 123 (27.8 %) 319 (72.2 %) 1116 (49.3 %) 1147 (50.7 %)
Former-smoker 174 (23.2 %) 577 (76.8 %) 1317 (47.6 %) 1450 (52.4 %)
Never-smoker 1159 (22.6 %) 3966 (77.4 %) 1065 (44.6 %) 1324 (55.4 %)
H. pylori Ab <0.0001* 0.6446
Negative 1003 (21.5 %) 3665 (78.5 %) 2474 (47.0 %) 2793 (53.0 %)
Positive 453 (27.5 %) 1197 (72.6 %) 1024 (47.6 %) 1128 (52.4 %)
FLD: fatty liver disease, MS: metabolic syndrome, Ab: antibody. By applying the Fisher’s exact test, p values were calculated. The level of significance was set below
0.01 (*).
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Table 3 Multivariate analyses evaluating association between the presence of fatty liver disease (FLD) and 9 selected











BMI 143.5 4.8 <0.0001* 102.5 3.7 <0.0001*
ALT 25.8 5.1 <0.0001* 75.7 13.1 <0.0001*
Age 34.3 3.5 <0.0001* 17.2 2.8 <0.0001*




−8.1 3.7 0.0270 −5.9 2.8 0.0371
Daily-drinker 8.5 3.7 0.0209 −8.4 2.9 0.0040*
MS
Positive 10.2 5.9 0.0804 16.4 3.2 <0.0001*
GGT 5.3 3.1 0.0919 4.0 4.1 0.3399
T-Bil −3.1 3.3 0.3386 1.4 2.4 0.5555
H. pylori
Positive 1.0 3.1 0.7558 −2.8 2.5 0.2642
MS: metabolic syndrome, C.I.: confidence interval, Ab: antibody, Using the logistic regression analysis, p values were calculated. The level of significance was set
below 0.01 (*).
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(NAFLD) based on the univariate analysis
Furthermore, we analyzed the 5,289 subjects free from al-
cohol influence to evaluate the relationship between
NAFLD and background factors including H. pylori infec-
tion status. We analyzed 19 continuous variables and 3
categorized variables and their association with fatty liver
disease (Tables 4 and 5). Among the 22 examined factors,
weight, BMI, AST, ALT, GGT, PLT, TC, HDL-C, TG,
HbA1c, FBS, SBP, DBP, waist girth, and MS were statisti-
cally significant in both genders. Age, height, T-Bil, ALB,
and smoking habit were statistically significant in only one
gender. However, regardless of gender, H. pylori infection
status was not associated with the presence of NAFLD.
According to the results of univariate analyses and
multicollinearity (0.9024 in female and 0.8841 in male
between weight and BMI, 0.8626 in female and 0.8440 in
male between AST and ALT), we excluded height,
weight, AST, T-Bil, and smoking habit from the next
multivariate analysis. We adopted MS as a representative
of waist girth, TC, HDL-C, LDL-C, TG, FBS, HbA1c,
SBP and DBP. Consequently, we chose the following
seven variables for multivariate analysis: Age, BMI, ALT,
GGT, PLT, MS, and H. pylori infection status.Associated factors for non-alcoholic fatty liver disease
(NAFLD) based on the multivariate analysis
As shown in Table 6, the generalized regression analysis dis-
played that BMI, ALT, and PLT were positively associated
with the presence of NAFLD. Age was positively associatedwith NAFLD only in females, whereas MS was positively
associated only in males. Like FLD, H. pylori infection sta-
tus did not show significant association with NAFLD, re-
gardless of gender.
Discussion
Background factors for FLD
As for FLD, BMI, ALT, age and PLT were positively associ-
ated with the presence of FLD in both genders, which is
concurrent with the recent study report from Japan [54].
Although alcohol intake has been regarded as a main
cause for fatty liver for a long time [1,55-58], our result
did not demonstrate a significant positive association be-
tween the frequency of alcohol intake and the presence
of fatty liver. Occasional alcohol intake tended to be
negatively associated with fatty liver in both genders,
similarly to a recent report [8]. (Table 3). There is a pos-
sibility that the negative association of alcohol intake to
FLD in daily-drinking males is attributed to the design
of this study, since the evaluation of amounts of alcohol
intake was not quantitatively accurate. To validate our
result; the association between alcohol and fatty liver
may not be as significant as previously reported, more
detailed information of alcohol intake and careful setup
of the study cohort will be needed in future studies.
Background factors for NAFLD
As for NAFLD, BMI, ALT, and PLT showed positive asso-
ciation. Unlike FLD, age was positively associated with
the presence of NAFLD only in females (Table 6). Female
gender, age, diabetes mellitus, hyperinsulinaemia, obesity
Table 4 Characteristics of the alcohol-free 5,289 subjects (3,473 females and 1,816 males) focusing on the presence of











Age (years old) 50.8 ± 8.1 47.6 ± 8.9 <0.0001* 47.6 ± 8.6 47.4 ± 10.1 0.5126
Height (cm) 156.9 ± 5.4 157.8 ± 5.5 <0.0001* 170.7 ± 5.8 170.9 ± 6.0 0.4956
Weight (kg) 61.8 ± 9.8 51.2 ± 6.3 <0.0001* 72.8 ± 10.0 63.8 ± 8.0 <0.0001*
BMI (kg/m2) 25.1 ± 3.7 20.5 ± 2.3 <0.0001* 25.0 ± 3.0 21.8 ± 2.3 <0.0001*
AST (IU/l) 21.4 ± 9.2 19.0 ± 5.4 <0.0001* 23.8 ± 10.6 20.0 ± 5.3 <0.0001*
ALT (IU/l) 23.5 ± 17.7 16.2 ± 7.8 <0.0001* 35.1 ± 30.7 21.3 ± 9.4 <0.0001*
GGT (IU/l) 26.4 ± 24.6 18.2 ± 14.8 <0.0001* 40.5 ± 41.0 26.6 ± 22.4 <0.0001*
T-Bil (mg/dl) 0.71 ± 0.26 0.74 ± 0.26 <0.0004* 0.85 ± 0.36 0.86 ± 0.37 0.5524
ALB (g/dl) 4.26 ± 0.22 4.24 ± 0.21 0.0148 4.41 ± 0.23 4.35 ± 0.22 <0.0001*
PLT (104/μl) 26.1 ± 6.0 23.7 ± 5.6 <0.0001* 24.7 ± 5.1 22.9 ± 4.9 <0.0001*
TC (mg/dl) 213.2 ± 33.4 201.2 ± 33.6 <0.0001* 207.4 ± 32.9 192.6 ± 29.9 <0.0001*
HDL-C (mg/dl) 62.9 ± 14.0 74.1 ± 15.0 <0.0001* 50.5 ± 10.7 59.5 ± 13.8 <0.0001*
LDL-C (mg/dl) 136.0 ± 31.8 118.2 ± 30.3 <0.0001* 138.6 ± 29.5 121.3 ± 27.8 <0.0001*
TG (mg/dl) 107.8 ± 71.0 69.1 ± 31.2 <0.0001* 144.1 ± 92.0 91.6 ± 47.7 <0.0001*
HbA1c (%) 5.55 ± 0.54 5.34 ± 0.35 <0.0001* 5.51 ± 0.63 5.31 ± 0.40 <0.0001*
FBS (mg/dl) 94.5 ± 14.7 88.1 ± 9.1 <0.0001* 98.4 ± 17.0 92.2 ± 8.5 <0.0001*
SBP (mmHg) 119.4 ± 16.8 107.7 ± 14.4 <0.0001* 118.6 ± 14.5 111.2 ± 13.3 <0.0001*
DBP (mmHg) 74.2 ± 10.6 66.9 ± 9.5 <0.0001* 74.9 ± 9.4 70.0 ± 8.8 <0.0001*
Waist (cm) 87.3 ± 8.7 75.7 ± 6.5 <0.0001* 87.3 ± 7.5 78.6 ± 6.6 <0.0001*
NAFLD: non-alcoholic fatty liver disease. Data show mean ± SD (standard deviation) of each variable. By applying the Welch’s t test or Wilcoxon analysis, p values
were calculated. The level of significance was set below 0.01 (*).
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itional risk factors for NAFLD [3,59-61]. Our results de-
noted the same tendency of these previous reports, but
MS wasn’t associated with the presence of NAFLD in
females.Table 5 Characteristics of the alcohol-free 5,289 subjects (3,4








Non-MS 838 (24.5 %) 2590 (75.6 %)
MS 43 (95.6 %) 2 (4.4 %)
Smoking 0.3
Current-smoker 54 (29.4 %) 130 (70.7 %)
Former-smoker 71 (24.0 %) 225 (76.0 %)
Never-smoker 756 (25.3 %) 2237 (74.7 %)
H. pylori Ab 0.0
Negative 610 (24.2 %) 1907 (75.8 %)
Positive 271 (28.4 %) 685 (71.7 %)
NAFLD: non-alcoholic fatty liver disease, MS: metabolic syndrome, Ab: antibody. By app
set below 0.01 (*).Association between H. pylori and FLD including NAFLD
Concerning H. pylori infection, neither FLD nor NAFLD
displayed a significant association in multivariate ana-
lysis regardless of gender, though H. pylori infection









793 (47.2 %) 886 (52.8 %)
128 (93.4 %) 9 (6.6 %)
913 0.0033*
289 (54.4 %) 242 (45.6 %)
284 (53.7 %) 245 (46.3 %)
348 (46.0 %) 408 (54.0 %)
145 0.8742
669 (50.6 %) 654 (49.4 %)
252 (51.1 %) 241 (48.9 %)
lying the Fisher’s exact test, p values were calculated. The level of significance was
Table 6 Multivariate analysis evaluating association between NAFLD and 7 selected variables among the non-drinking











BMI 113.3 4.9 <0.0001* 55.3 3.7 <0.0001*
ALT 21.6 6.1 0.0004* 53.8 6.5 <0.0001*
Age 25.0 3.5 <0.0001* 3.7 2.6 0.1607
PLT 13.8 3.0 <0.0001* 11.8 2.5 <0.0001*
MS
Positive 5.9 5.0 0.2354 11.6 4.5 0.0092*
GGT 2.3 3.4 0.4975 0.24 3.9 0.9508
H. pylori
Positive −1.2 3.1 0.7017 −1.8 2.6 0.4764
MS: metabolic syndrome, Ab: antibody, C.I.: confidence interval. Using the logistic regression analysis, p values were calculated. The level of significance was set
below 0.01 (*).
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environment caused by chronic H. pylori infection has
no or marginal influence on the development of fatty
liver. These results are consistent with some previous re-
ports [35,36].
Limitations and future prospects
The first limitation of our study is the study design itself
(i.e., cross-sectional study). A single point analysis can-
not obtain accurate results, since fatty liver is thought to
emerge as a consequence of several risk factors over a
number of years. The second limitation is reliability of
ultrasonography as a diagnostic tool for NAFLD. Diagno-
sis by ultrasonography has inevitable limitations due to
low sensitivity for mild steatosis, inability to differentiate
mild fibrosis from steatosis, and inaccurate quantification
of fatty infiltration [62]. And more, interobserver and
intraobserver variability in the sonographic assessment of
fatty liver are well known [63]. Nevertheless, these short-
comings were thought to be minimal, because well-trained
operators and gastroenterologists in a single hospital diag-
nosed fatty liver with prescribed findings written above in
this study. In fact, we have already reported some study re-
sults based on our ultrasonography-based diagnoses
[31,64]. The third limitation is the diagnostic accuracy of
H. pylori infection based on serology. Though urea breath
test (UBT) is superior to the serology test, the serology test
is used due to its non-invasiveness and cost-effectiveness
in our medical check up, which routinely has blood draw-
ing. The accuracy of serology test in diagnosing H. pylori
infection in this study was acceptable, since our recent
study using the same study population showed that 97.8%
(1,638 of 1,674) of the subjects with sero-positivity of H.
pylori had chronic atrophic gastritis[49]. The fourth limi-
tation is the small number of female participants. We in-
ferred that undetected association between MS and FLDincluding NAFLD might be due to the small number of fe-
male subjects who met MS criteria.
For the future prospects, we will follow this cohort to
reveal the long-term effect of various associated factors
upon FLD and NAFLD, such as developing NASH, liver
cirrhosis, hepatocellular carcinoma, and so on.
Conclusions
Body mass index (BMI), serum ALT, and platelet count were
positively associated with the presence of fatty liver disease
(FLD) and non-alcoholic fatty liver disease (NAFLD) in both
genders. On the other hands, Helicobacter pylori infection
was not associated with either FLD or NAFLD.
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